MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Gastroenterology_Gastrointestinal (to include Liver, Pancreas & metabolic dysfunction-associated steatotic liver disease (MASLD), Gout, MASH (Metabolic dysfunction-associated steatohepatitis), formerly, NASH (Non-Alcoholic SteatoHepatitis)Non-Alcoholic SteatoHepatitis (NASH)
Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT)
*Key People: Intercept
Parents
Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT)
Children
2020: Intercept Pharma to Cut 170 Employees in Wake of CRL for NASH Treatment
2023: Intercept to abandon NASH research, lay off staff after FDA drug rejection
Gail Cawkwell, Intercept Pharmaceuticals, Inc. - SVP of Medical Affairs, Safety & Pharmacovigilance (2021)
Jerome B. Durso, Intercept Pharmaceuticals, Inc. - President & CEO (2021)
Jerry Durso is chairman, president and CEO, Altimmune, former, CEO, Intercept Pharmaceuticals (2026)
Number of employees: 341 (2022)
Ryan Martinez, Head of Diversity, Equity and Inclusion, Intercept Pharmaceuticals (2021)
Sandip S. Kapadia, Intercept Pharmaceuticals, Inc. - CFO, Treasurer & Principal Accounting Officer (2021)
Jumps
Finance & Acquisitions: Intercept
Organization & Developments: Intercept